,
Woury Sow,
Mamoudou Salif Djigo,
Gora Thiaw,
Hien Mwinbele Stephane,
El Hadji Amadou Lamine Bathily,
Radioiodine therapy, a treatment method for hyperthyroidism, has been practiced in Senegal since 2016. The objective of our study was to identify predictive factors for the success or failure of radioiodine therapy in the management of hyperthyroidism in Senegal. A retrospective study was initiated in the nuclear medicine department of the Idrissa Pouye Hospital in Grand Yoff. It included the medical records of 172 patients followed for hyperthyroidism and treated with iodine-131. Demographic, clinical, paraclinical, and therapeutic aspects, as well as the evaluation of thyroid function at 3 and 6 months post-radioiodine therapy, were studied. The therapeutic efficacy at 3 months was 44.1%. Among the 17 patients who failed treatment, 12 were under 50 years of age. No statistically significant relationship was found between treatment failure and age (p = 0.877. However, the difference was statistically significant between men and women in terms of treatment failure (p=0.043). Vascular goiter, etiology, initial antithyroid drug use, and a short interval between antithyroid drugs (ATDs) discontinuation were factors contributing to treatment failure. A strong correlation existed between therapeutic efficacy and the administered dose (p=0.000). The 6-month success rate was 62.4%. The final therapeutic efficacy was 73.75%. Radioiodine therapy is an effective treatment for hyperthyroidism, achieving a high remission rate.
| Published in | European Journal of Biophysics (Volume 14, Issue 1) |
| DOI | 10.11648/j.ejb.20261401.11 |
| Page(s) | 1-7 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2026. Published by Science Publishing Group |
Hyperthyroidism, Radioiodine Therapy, Therapeutic Success, Therapeutic Failure
| [1] | Bahn, R. S. «Graves’ disease.» New England Journal of Medicine, 2010 Feb 25; 362(8): 726-38. |
| [2] | Bathily EHAL, Diop O, Ndong B, Djigo MS, Thiaw G, Gueye K, et al. Treatment of hyperthyroidism with iodine-131: preliminary activity report from the nuclear medicine department at Grand Yoff General Hospital in Dakar. Nuclear Medecine. 2020; 44(2): 130131. |
| [3] | Bathily EHAL, Badiane SM, Djigo MS, Thiaw G, Gueye K, et al. Iodine 131 Treatment in Graves’ Disease in a West African Country: Preliminary Study about 25 Cases in Senegal. Open Journal of Biophysics, 2024, 14, 56-72. |
| [4] | Brent GA. Graves’ Disease. N Engl J Med. 2008; 358(24): 25942605. |
| [5] | Diagne N, Faye A, Ndao AC, Djiba B, Kane BS, Ndongo S, Pouye A. Epidemiological, clinical, therapeutic, and progressive aspects of Graves' disease in internal medicine at Le Dantec University Hospital in Dakar, Senegal. Pan Afr Med J. 2016. |
| [6] | Diop O, Sow W, Ndong B, Bathily EAL, Djigo MS, et al. Radio-iodine therapy of graves’ disease in the developing countries: Senegalese experience about 25 cases. Dakar Med. 2018; 63(1). |
| [7] | Erem C, Kandemir N, Hacihasanoglu A, Ersoz HO Ukinc K, Kocak M. E. Radioiodine Treatment of Hyperthyroidism: Prognostic Factors Affecting Outcome. 2004; 25(1): 5560. |
| [8] | Feleh EE, Bchir N, Jaidane A, Mahjoubi S, Zouaoui C, Ouertan H. Clinical and paraclinical profile of Graves' disease. SFE Poitiers 2017 / Annals of Endocrinology. 2017; 78 326–352. |
| [9] | Goichot B, Caron Ph, Landron F, Bouee S. Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationships with age, aetiology and hormonal parameters. Clinical Endocrinology. 2016; 84: 445- 451. |
| [10] | John EEM, Karounwi O, Ogunjobi, et al. Effectiveness of Fixed Dose Radioactive Iodine (RAI) for the Treatment of Hyperthyroidism: Experience of a Teaching Hospital in South West Nigeria. Mol Imaging Radionucl Ther. 2013; 22(2): 36–41. |
| [11] | Kartamihardja AHS, Massora S. The Influence of Antithyroid Drug Discontinuation to the Therapeutic Efficacy of 131I in Hyperthyroidism. World J Nucl Med. 2016; 15(2): 8184. |
| [12] |
Khessairi N, Riden D, Yazidi M, Grira W, Oueslati I, Chaker F, et al. Predictive factors for resistance to RAI therapy in Graves' disease. Annals of Endocrinology. 2020; 81(4): 346.
https://doi.org/10.1016/j.amjsurg. 2021.03.068 |
| [13] | Luster, M., & Hennessey, J. V. The role of antithyroid medications in the management of hyperthyroidism. *Endocrine Reviews*, 2019, 40(3), 123-145. |
| [14] | Madu NM, Skinner C, Oyibo SO. Cure Rates After a Single Dose of Radioactive Iodine to Treat Hyperthyroidism: The Fixed-Dose Regimen. Cureus.; 14(8): 28316. |
| [15] | Mazzaferri, E. L., & Jhiang, S. M. Long-term impact of initial surgical and medical therapy on the outcome of hyperthyroidism." *Thyroid*, 1994, 4(2), 117-124. |
| [16] | Nwatsock JF, Taieb D, Tessonnier L, Mancini J, Dong-A-Zok F, Mundler O. Radioiodine thyroid ablation in Graves’ hyperthyroidim: Merits and pitfalls. World J Nucl Med. 2012; 11(1): 7-11. |
| [17] | Rezgani I, Meddeb I, Yeddeas I, Slim I, Mhiri A, Ben Slimene MF. Comparative study of the efficacy of iodine therapy in Graves' disease and toxic thyroid nodules. Annals of Endocrinology. 2017; 78(4): 337. |
| [18] | Ross DS, Burch HB, Cooper DS, et al. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. American Thyroid Association. Thyroid. 2016; 26(10): 1343- 1421. |
| [19] | Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. 2014 Failure of Radioactive Iodine in the Treatment of Hyperthyroidism. Ann Surg Oncol.; 21(13): 41744180. |
APA Style
Diop, O., Sow, W., Djigo, M. S., Thiaw, G., Stephane, H. M., et al. (2026). Research into Predictive Factors for the Success or Failure of Radioiodine Therapy in the Treatment of Hyperthyroidism in Senegal. European Journal of Biophysics, 14(1), 1-7. https://doi.org/10.11648/j.ejb.20261401.11
ACS Style
Diop, O.; Sow, W.; Djigo, M. S.; Thiaw, G.; Stephane, H. M., et al. Research into Predictive Factors for the Success or Failure of Radioiodine Therapy in the Treatment of Hyperthyroidism in Senegal. Eur. J. Biophys. 2026, 14(1), 1-7. doi: 10.11648/j.ejb.20261401.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ejb.20261401.11,
author = {Ousseynou Diop and Woury Sow and Mamoudou Salif Djigo and Gora Thiaw and Hien Mwinbele Stephane and El Hadji Amadou Lamine Bathily and Boucar Ndong},
title = {Research into Predictive Factors for the Success or Failure of Radioiodine Therapy in the Treatment of Hyperthyroidism in Senegal},
journal = {European Journal of Biophysics},
volume = {14},
number = {1},
pages = {1-7},
doi = {10.11648/j.ejb.20261401.11},
url = {https://doi.org/10.11648/j.ejb.20261401.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejb.20261401.11},
abstract = {Radioiodine therapy, a treatment method for hyperthyroidism, has been practiced in Senegal since 2016. The objective of our study was to identify predictive factors for the success or failure of radioiodine therapy in the management of hyperthyroidism in Senegal. A retrospective study was initiated in the nuclear medicine department of the Idrissa Pouye Hospital in Grand Yoff. It included the medical records of 172 patients followed for hyperthyroidism and treated with iodine-131. Demographic, clinical, paraclinical, and therapeutic aspects, as well as the evaluation of thyroid function at 3 and 6 months post-radioiodine therapy, were studied. The therapeutic efficacy at 3 months was 44.1%. Among the 17 patients who failed treatment, 12 were under 50 years of age. No statistically significant relationship was found between treatment failure and age (p = 0.877. However, the difference was statistically significant between men and women in terms of treatment failure (p=0.043). Vascular goiter, etiology, initial antithyroid drug use, and a short interval between antithyroid drugs (ATDs) discontinuation were factors contributing to treatment failure. A strong correlation existed between therapeutic efficacy and the administered dose (p=0.000). The 6-month success rate was 62.4%. The final therapeutic efficacy was 73.75%. Radioiodine therapy is an effective treatment for hyperthyroidism, achieving a high remission rate.},
year = {2026}
}
TY - JOUR T1 - Research into Predictive Factors for the Success or Failure of Radioiodine Therapy in the Treatment of Hyperthyroidism in Senegal AU - Ousseynou Diop AU - Woury Sow AU - Mamoudou Salif Djigo AU - Gora Thiaw AU - Hien Mwinbele Stephane AU - El Hadji Amadou Lamine Bathily AU - Boucar Ndong Y1 - 2026/01/16 PY - 2026 N1 - https://doi.org/10.11648/j.ejb.20261401.11 DO - 10.11648/j.ejb.20261401.11 T2 - European Journal of Biophysics JF - European Journal of Biophysics JO - European Journal of Biophysics SP - 1 EP - 7 PB - Science Publishing Group SN - 2329-1737 UR - https://doi.org/10.11648/j.ejb.20261401.11 AB - Radioiodine therapy, a treatment method for hyperthyroidism, has been practiced in Senegal since 2016. The objective of our study was to identify predictive factors for the success or failure of radioiodine therapy in the management of hyperthyroidism in Senegal. A retrospective study was initiated in the nuclear medicine department of the Idrissa Pouye Hospital in Grand Yoff. It included the medical records of 172 patients followed for hyperthyroidism and treated with iodine-131. Demographic, clinical, paraclinical, and therapeutic aspects, as well as the evaluation of thyroid function at 3 and 6 months post-radioiodine therapy, were studied. The therapeutic efficacy at 3 months was 44.1%. Among the 17 patients who failed treatment, 12 were under 50 years of age. No statistically significant relationship was found between treatment failure and age (p = 0.877. However, the difference was statistically significant between men and women in terms of treatment failure (p=0.043). Vascular goiter, etiology, initial antithyroid drug use, and a short interval between antithyroid drugs (ATDs) discontinuation were factors contributing to treatment failure. A strong correlation existed between therapeutic efficacy and the administered dose (p=0.000). The 6-month success rate was 62.4%. The final therapeutic efficacy was 73.75%. Radioiodine therapy is an effective treatment for hyperthyroidism, achieving a high remission rate. VL - 14 IS - 1 ER -
Faculty of Medicine, Pharmacy and Odontology, Cheikh Anta Diop University, Dakar, Senegal;Department of Nuclear Medicine, Hospital Dalal Jamm, Dakar, Senegal
Faculty of Medicine, Pharmacy and Odontology, Cheikh Anta Diop University, Dakar, Senegal
Faculty of Medicine, Pharmacy and Odontology, Cheikh Anta Diop University, Dakar, Senegal;Department of Nuclear Medicine, Idrissa Pouye General Hospital, Dakar, Senegal
Faculty of Medicine, Pharmacy and Odontology, Cheikh Anta Diop University, Dakar, Senegal
Faculty of Medicine, Pharmacy and Odontology, Cheikh Anta Diop University, Dakar, Senegal
Faculty of Medicine, Pharmacy and Odontology, Cheikh Anta Diop University, Dakar, Senegal;Department of Nuclear Medicine, Idrissa Pouye General Hospital, Dakar, Senegal
Information